microRNAs put their signatures on the heart
2007; American Physical Society; Volume: 31; Issue: 3 Linguagem: Inglês
10.1152/physiolgenomics.00206.2007
ISSN1531-2267
Autores Tópico(s)RNA modifications and cancer
ResumoEditorial FocusmicroRNAs put their signatures on the heartEva van Rooij, and Eric N. OlsonEva van RooijDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, and Eric N. OlsonDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TexasPublished Online:01 Nov 2007https://doi.org/10.1152/physiolgenomics.00206.2007This is the final version - click for previous versionMoreSectionsPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat few would disagree that there is a major need for innovative therapies for heart disease. Traditional drug targets, such as cell surface receptors, enzymes, and ion channels, have posed significant challenges to the development of new therapeutics for restoring function to the failing heart. Consequently, many major pharmaceutical companies have abandoned their heart failure programs, feeling the disease is simply too complex, despite being a major cause of human morbidity and mortality with a staggering impact on the health care system (estimated to exceed $30 billion/yr). Thus, it seems an opportune time to think “outside the box” about unconventional disease mechanisms and therapeutic approaches for heart failure. Rarely has such an opportunity existed to unveil and exploit an entirely new biology of disease, as has been provided by the recent discovery of microRNAs as markers and modulators of heart failure and pathological cardiac remodeling (9).microRNAs are ∼22-nucleotides long and act as negative regulators of gene expression by inhibiting mRNA translation or promoting mRNA degradation. There are estimated to be >1,000 microRNAs encoded by the human genome, each of which acts on many mRNAs. Conversely, individual mRNAs are commonly targeted by multiple microRNAs, allowing for enormous combinatorial complexity and regulatory potential. An especially powerful aspect of miRNA function is the ability of individual miRNAs to coordinately regulate target genes encoding proteins with related functions (e.g., cell growth or metabolism). Therein lies the power of single microRNAs to modulate complex physiological or disease phenotypes by regulating entire functional networks, in contrast to classical drugs, which act on specific cellular targets.Numerous recent studies point to the involvement of microRNAs in the regulation of cellular responses to stress. microRNAs have been identified, for example, that are upregulated in response to stresses, such as hypoxia, nutrient deprivation, and DNA damage (5). The possibility that microRNAs might participate in heart disease was first suggested by the discovery of distinctive patterns of microRNA expression in the hearts of normal mice and mice that suffered from heart disease (10). Specific microRNAs were up- or downregulated in mice that were subjected to thoracic aortic banding (TAB), a potent stimulus for pathological hypertrophy, or in response to constitutive activation of calcineurin, a stress-inducible mediator of the hypertrophic response. Importantly, many of these microRNAs were also dysregulated in failing human hearts, suggesting they established a diagnostic molecular signature for cardiac pathogenesis (10). Based on a handful of genetic studies in mice, it is becoming increasingly clear that miRNAs are indeed actively involved in cardiac remodeling, growth, conductance and contractility (1, 10, 11, 13–15).A study by Ikeda and coworkers (2a) in this issue of Physiological Genomics adds to a series of papers describing signature patterns of microRNAs in hypertrophic and failing hearts from humans and animal models (2, 6, 7–9). Using a bead-based platform to measure the expression of 428 miRNAs, Ikeda and coworkers compared miRNA expression in three different types of human heart disease (ischemic cardiomyopathy, dilated cardiomyopathy, and aortic stenosis) with normal heart. Among the 87 miRNAs detected in the heart, roughly half were differentially expressed in at least one disease group, while seven miRNAs were regulated in the same direction in all three disease states. Although several studies already indicated miRNA expression to be regulated in human heart disease (1, 8, 10, 13), this study is the first to show commonalities in expression between distinct disease etiologies. These divergent miRNA expression patterns point to miRNAs as biomarkers for subtle phenotypic differences and disease progression and imply that they are active participants in the disease processes.The involvement of miRNAs in human heart disease is exciting and promising for future therapeutic applications but still requires verification and functional validation. The study presented by Ikeda and colleagues (2a) nicely complements the miRNA expression data shown in other studies. Although there is substantial overlap in the expression patterns of the regulated miRNAs in the different studies, there are some discrepancies that require further validation. For example, a previous study by Care et al. (1) showed miR-133 to be downregulated in patients suffering from hypertrophic cardiomyopathy, whereas this microRNA was unchanged in the studies performed by the Pu group (2a) and Thum et al. (8). Given the apparent specificity of miRNA expression for relatively subtle variations in disease state, the disparities between these studies may reflect variations in the progression of disease of the different samples tested or even variations in miRNA expression in different regions of the ventricular wall that were taken for biopsies. Indeed, cardiomyocyte heterogeneity within different regions of the heart has recently been appreciated as an important facet of cardiac function. Since new microRNAs are being discovered almost on a daily basis, and the technology for microRNA microarrays remains to be further optimized, it is also likely that current expression data are still incomplete and many additional microRNAs with roles in heart disease remain to be identified.Although it is now clear that cardiac disease is accompanied by dramatic changes in miRNA expression, the burning question is whether microRNAs are simply biomarkers for heart disease or whether they actually regulate the disease process. Several recent studies in genetically modified mice argue strongly for the latter. MiR-195, which is upregulated during hypertrophy, is sufficient when overexpressed in the hearts of transgenic mice to induce pathological cardiac growth culminating in ventricular dilatation, myocyte disarray, and cardiac sudden death (10). Thus, this microRNA appears to be sufficient to drive the disease process. Conversely, miR-208, a cardiac-specific microRNA encoded by an intron of the α-myosin heavy chain (MHC) gene, is required for pathological cardiac growth, fibrosis, and upregulation of β-MHC expression in response to TAB, calcineurin activation, and hypothyroidism (11). Knockdown of miR-133 expression with antisense oligonucleotides has also been shown to cause cardiac hypertrophy, suggesting an essential role for this microRNA in the suppression of myocyte growth (1). Nevertheless, not all microRNAs that are modulated during heart disease are likely to be directly involved in the disease process. In this regard, among the 24 miRNAs that Ikeda et al. (2a) found to be upregulated in human heart disease, miR-214 was the most highly upregulated in all three groups. However, cardiac-specific overexpression of miR-214 in transgenic mice failed to induce a cardiac phenotype (10).The manipulation of microRNAs poses several unique opportunities for therapeutic development. In classical drug discovery, it can take years to identify therapeutic targets, devise and execute high-throughput screens, and eventually find small molecules that inhibit those targets, but that's just the beginning. microRNAs offer the possibility of leapfrogging over these preliminary studies, once the microRNA that regulates the disease is known. The use of chemically modified oligonucleotides to target either a specific miRNA or to disrupt the binding between a miRNA and a specific mRNA target in vivo represents a potentially effective means of inactivating pathological miRNAs.Developing microRNAs into therapeutics will also, undoubtedly, pose significant challenges, such as modes of delivery and duration of action. Methods for local delivery to the heart, through direct injection or via catheters or coated stents, will obviate these challenges and should make it possible to avoid off-target effects on noncardiac tissues. Moreover, given the infatuation of cardiologists with delivery procedures and devices, heart disease seems likely to be among the first therapeutic targets to succumb to microRNA based therapeutics.There is a sense of standing on the brink of a new revolution in understanding the molecular basis of disease based on the biology of microRNAs. The recent papers on microRNA signatures of the failing heart are harbingers of the future. The discovery of microRNAs that participate in heart disease and the analysis of their targets have the potential to reveal unanticipated disease mechanisms and facilitate novel therapeutic approaches. With 1,000 or more microRNAs encoded by the human genome, only a few of which have been analyzed, all things seem possible. We expect in the near future that microRNA-based diagnostics will be commonplace and that microRNA-based therapeutics will play a major role in the armamentarium for heart failure. Stay tuned!DISCLOSURESThe authors are cofounders of Miragen Therapeutics, a company based on the therapeutic application of miRNAs in heart disease.REFERENCES1 Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13: 613–618, 2007.Crossref | PubMed | ISI | Google Scholar2 Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. microRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 170: 1831–1840, 2007.Crossref | PubMed | ISI | Google Scholar2a Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT. Altered microRNA expression in human heart disease. Physiol Genomics (August 21, 2007). doi:10.1152/physiolgenomics.00144.2007.Google Scholar3 Krutzfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, Manoharan M, Stoffel M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35: 2885–2892, 2007.Crossref | PubMed | ISI | Google Scholar4 Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689, 2005.Crossref | PubMed | ISI | Google Scholar5 Leung AKL, Sharp PA. microRNAs: a safeguard against turmoil? Cell 130: 581–585, 2007.Crossref | PubMed | ISI | Google Scholar6 Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. microRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100: 416–424, 2007.Crossref | PubMed | ISI | Google Scholar7 Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42: 1137–1141, 2007.Crossref | PubMed | ISI | Google Scholar8 Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. microRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116: 258–267, 2007.Crossref | PubMed | ISI | Google Scholar9 Van Rooij E, Olson EN. microRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117: 2369–2376, 2007.Crossref | PubMed | ISI | Google Scholar10 Van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103: 18255–18260, 2006.Crossref | PubMed | ISI | Google Scholar11 Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316: 575–579, 2007.Crossref | PubMed | ISI | Google Scholar12 Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 212: 285–292, 2007.Crossref | PubMed | ISI | Google Scholar13 Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486–491, 2007.Crossref | PubMed | ISI | Google Scholar14 Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129: 303–317, 2007.Crossref | PubMed | ISI | Google Scholar15 Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436: 214–220, 2005.Crossref | PubMed | ISI | Google Scholar Download PDF Back to Top Next FiguresReferencesRelatedInformationCited ByThe microRNA Expression Profiling in Heart Failure: A Systematic Review and Meta-Analysis15 June 2022 | Frontiers in Cardiovascular Medicine, Vol. 9Metformin relieves H/R-induced cardiomyocyte injury through miR-19a/ACSL axis - possible therapeutic target for myocardial I/R injuryToxicology and Applied Pharmacology, Vol. 19MicroRNA-1-Mediated Inhibition of Cardiac Fibroblast Proliferation Through Targeting Cyclin D2 and CDK617 May 2019 | Frontiers in Cardiovascular Medicine, Vol. 6A novel murine model for arrhythmogenic cardiomyopathy points to a pathogenic role of Wnt signalling and miRNA dysregulation10 October 2018 | Cardiovascular Research, Vol. 115, No. 4Platelets: Functional Biomarkers of Epigenetic Drift30 January 2019Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise30 March 2018 | Oncotarget, Vol. 9, No. 24The noncoding-RNA landscape in cardiovascular health and diseaseNon-coding RNA Research, Vol. 3, No. 1Nonhuman Primates and Translational Research—Cardiovascular Disease28 August 2017 | ILAR Journal, Vol. 58, No. 2ox-LDL increases microRNA-29a transcription through upregulating YY1 and STAT1 in macrophages23 July 2017 | Cell Biology International, Vol. 41, No. 9ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis7 May 2017 | Oncotarget, Vol. 8, No. 29A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks22 March 2017 | PLOS ONE, Vol. 12, No. 3Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?Pharmacology & Therapeutics, Vol. 170Overexpression of Chromosome 21 miRNAs May Affect Mitochondrial Function in the Hearts of Down Syndrome FetusesInternational Journal of Genomics, Vol. 2017Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction)Journal of Molecular and Cellular Cardiology, Vol. 94Upregulation of miRNA-155 expression by OxLDL in dendritic cells involves JAK1/2 kinase and transcription factors YY1 and MYB11 March 2016 | International Journal of Molecular Medicine, Vol. 37, No. 5miR-23a binds to p53 and enhances its association with miR-128 promoter10 November 2015 | Scientific Reports, Vol. 5, No. 1Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy27 June 2014 | Human Reproduction Update, Vol. 20, No. 6How the proteome packages the genome for cardiovascular development28 August 2014 | PROTEOMICS, Vol. 14, No. 19miR-17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodelingThe FASEB Journal, Vol. 27, No. 10Regulation of miR-155 biogenesis in cystic fibrosis lung epithelial cells: Antagonistic role of two mRNA-destabilizing proteins, KSRP and TTPBiochemical and Biophysical Research Communications, Vol. 433, No. 4Cardiac Myocyte–Fibroblast Interactions and the Coronary Vasculature18 September 2012 | Journal of Cardiovascular Translational Research, Vol. 5, No. 6Non-cardiomyocyte microRNAs in heart failure16 December 2011 | Cardiovascular Research, Vol. 93, No. 4The role of miRNAs in complex formation and control16 December 2011 | Bioinformatics, Vol. 28, No. 4Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23aJournal of Biological Chemistry, Vol. 287, No. 1Elevated miR-155 Promotes Inflammation in Cystic Fibrosis by Driving Hyperexpression of Interleukin-8Journal of Biological Chemistry, Vol. 286, No. 13MicroRNA-29a regulates pro-inflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells4 February 2011 | FEBS Letters, Vol. 585, No. 4MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells12 January 2011 | FEBS Letters, Vol. 585, No. 3Cardiac Cell Therapy: Present and Future29 July 2011Identification and quantitative analyses of microRNAs located in the distal axons of sympathetic neurons28 June 2010 | RNA, Vol. 16, No. 8NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repressionQi Li, Xi Lin, Xiangsheng Yang, and Jiang Chang1 May 2010 | American Journal of Physiology-Heart and Circulatory Physiology, Vol. 298, No. 5Noncoding RNA for Presymptomatic Diagnosis of Age-Dependent DiseaseGene Profiling of the Failing Heart: Epigenetics4 March 2010Myocyte Enhancer Factor 2 Transcription Factors in Heart Development and DiseaseCardiac lineage selection: integrating biological complexity into computational models13 November 2009 | WIREs Systems Biology and Medicine, Vol. 1, No. 3Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling NetworksJournal of Biological Chemistry, Vol. 284, No. 40MicroRNA: a new entrance to the broad paradigm of systems molecular medicineMingyu Liang1 July 2009 | Physiological Genomics, Vol. 38, No. 2Cardiac gene regulatory networks in DrosophilaBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, Vol. 1789, No. 4MicroRNAs as a therapeutic target for cardiovascular diseasesJournal of Cellular and Molecular Medicine, Vol. 13, No. 4Pacemaker activity of the human sinoatrial node: Role of the hyperpolarization-activated current, IfInternational Journal of Cardiology, Vol. 132, No. 3Large-scale studies to identify biomarkers for heart disease: a role for proteomics?9 May 2009 | Expert Opinion on Medical Diagnostics, Vol. 3, No. 2Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer: Suppression of Tumorigenic Property of Lung Cancer Cells and Their Sensitization to Doxorubicin-Induced Apoptosis by miR-1Journal of Biological Chemistry, Vol. 283, No. 48Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis2 September 2008 | Proceedings of the National Academy of Sciences, Vol. 105, No. 35miRNAs: Effectors of Environmental Influences on Gene Expression and Disease16 February 2008 | Toxicological Sciences, Vol. 103, No. 2Translational Medicine: microRNAs: a new emerging class of players for disease diagnostics and gene therapy13 August 2007 | Journal of Cellular and Molecular Medicine, Vol. 12, No. 1 More from this issue > Volume 31Issue 3November 2007Pages 365-366 Copyright & PermissionsCopyright © 2007 the American Physiological Societyhttps://doi.org/10.1152/physiolgenomics.00206.2007PubMed17848602History Published online 1 November 2007 Published in print 1 November 2007 Metrics
Referência(s)